SUN-649 Higher Circulating Resistin Levels and Increased Frailty Risk in Older Adults: Implications Beyond Metabolic Function

Abstract Disclosure: B. Kim: None. J. Baek: None. S. Park: None. Objective: Despite the pleiotropic role of resistin as an adipokine, its association with frailty—an indicator of biologic age and overall well-being in humans—remains largely unexplored. This study aims to investigate the potential of circulating resistin as a biomarker for frailty. Methods: The study included 228 older adults aged 65 years or older who underwent a comprehensive geriatric assessment. Frailty was evaluated using both the phenotypic frailty model by Fried and the deficit-accumulation frailty index (FI) by Rockwood. Serum resistin levels were measured using a competitive enzyme-linked immunosorbent assay. Results: After adjusting for sex, age, and body mass index, serum resistin levels were 55.1% higher in individuals with phenotypic frailty than in robust controls (P < 0.001) and showed a positive correlation with the Rockwood FI (P = 0.025). Furthermore, for every 1 standard deviation increase in serum resistin levels, the risk of frailty nearly doubled (P = 0.009). When participants were divided into four groups based on serum resistin levels, individuals in the highest quartile had a 45% higher FI and exhibited a 12.9-fold higher odds ratio for frailty compared to those in the lowest quartile (P = 0.021 and 0.018, respectively). Conclusion: These findings suggest that circulating resistin may serve as a candidate blood-based biomarker for frailty, encompassing the multifaceted physical, cognitive, and social dimensions, extending beyond its well-established role in metabolic regulation. Presentation: Sunday, July 13, 2025